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Abstract: End-stage liver diseases are one of the leading causes of death in the world. Often orthotopic liver 
transplantation represents the final therapeutic choice. The limits of this approach are the scarcity of donor livers 
available, and the many side effects related to the administration of immune suppressants to the patients.  
Cellular therapy for liver diseases is increasingly being viewed as a promising strategy to provide hepatocytes to replenish 
the parenchymal cells of the organ. This technique suffers of some important limitations, such as the difficulty in isolating 
sufficient cell numbers (e.g. when adult or foetal hepatocytes are used for transplantation), the limited viability of isolated 
hepatocytes and, when applicable, the limited differentiation of stem cells (when hepatocyte-like cells are derived from 
hepatic or extra-hepatic progenitor populations). 
In recent years, perinatal stem cells have been proposed as reliable cellular populations which may be successfully used to 
derive hepatocyte-like cells. These cells feature key advantages over other adult stem cells: may be easily sourced from 
the tissues of origin, can be expanded ex vivo to obtain high cell numbers, may be differentiated towards hepatocyte-like 
cells. In addition, these cells feature relevant immunomodulatory and anti-inflammatory activities, and their sourcing is 
not limited by ethical concerns 
In the present review we analyze the molecular basis of hepatocyte biology and development, and discuss the recent 
advances in deriving hapatocyte-like cells from perinatal stem cells. Very recent papers on mesenchymal stem cells 
derived from bone marrow and adipose tissues are also comparatively discussed as prototypes of the use of adult extra-
hepatic stem cells. In our opinion, perinatal stem cells do represent a promising tool for liver regenerative medicine, and 
recent research reports further strengthened this perception and fostered further efforts by multiple research groups 
worldwide. 
Keywords: Mesenchymal stem cells, Wharton’s jelly, amniotic fluid, amniotic membrane, immune modulation, umbilical cord, 
hepatocyte differentiation, functional assays, inflammation, fibrosis, regenerative medicine, tissue repair. 
INTRODUCTION 
 The liver is a parenchymal organ which performs various 
critical functions: First, hepatocytes convert circulating 
glucose into glycogen, and may perform the inverse 
conversion when needed. Liver may act both as an exocrine  
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gland (via bile production), as well as an endocrine one (for 
the production of blood clotting factors, plasma proteins and 
other molecules). Moreover, the liver converts ammonia in 
urea (which is then excreted by the urinary system) and 
performs xenobiotic detoxification [1, 2]. 
 Hepatocytes represent about 80% of total liver mass, the 
remaining part of the organ is constituted by cholangiocytes, 
Kupffer cells, stellate (Ito) cells, hepatic specific natural 
killer and endothelial cells. Hepatocytes are polyhedral cells 
which are organized in anastomized laminae constituting the 
bulk of the morpho-functional units of liver: the hepatic 
lobules. The microscopic anatomy of these cells clearly 
shows the existence of a basal surface (vascular pole) 
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through which the hepatocytes secrete plasma proteins into 
sinusoids and perform all the other exchanges with blood. 
Their apical surface (biliary pole) is involved in bile 
secretion into intralobular biliar capillaries (which are 
bordered by hepatocytes) that later join the perilobular bile 
ducts (which are bordered by cholangiocytes) [3]. 
 Liver diseases globally constitute a major health concern 
worldwide, with hundreds of millions of affected people. 
Non-alcoholic fatty liver disease (NAFLD), autoimmune 
diseases, alcoholism, chronic hepatitis C and B, and drug-
induced hepatic disorders are the main causes of 
hepatopathies. Most of these conditions, if not prevented or 
properly treated, may lead to progressive liver injury, which 
may evolve into liver fibrosis, cirrhosis, portal hypertension, 
and even cancer [4]. 
 Orthotopic liver transplantation is still the final treatment 
for a number of end-stage liver diseases. However adverse 
events such as rejection and complications associated with 
long term immunosuppressant administration limit its 
therapeutic potential. Moreover, scarcity of donors and the 
high costs for the health system are other factors which 
caused the increased demand of alternative strategies. 
 Hepatocyte transplantation is viewed as a simpler and 
less invasive procedure. Despite the positive results obtained 
so far with this therapeutic approach, for example in the 
treatment of metabolic liver disorders, its usefulness for 
cirrhosis and acute liver failure is still limited. Moreover, 
scarcity of cadaveric livers, the limited replicative potential 
of infused hepatocytes, the damages induced from 
cryopreservation and the elevated cell numbers needed for 
transplantation, currently constitute important limits to the 
potential of hepatocyte transplantation [5]. 
 Also for these reasons, many researchers searched 
alternative sources of suitable cells for transplantation, such 
as adult stem cells. Two different adult stem cells groups 
were shown to possess differentiative capacity towards 
hepatocytes: hepatic stem cells (liver-resident progenitor cell 
populations) and extra-hepatic stem cells, such as bone 
marrow-derived mesenchymal stem cells (BM-MSC), 
hematopoietic stem cells (HSC), adipose tissue-derived 
mesenchymal stem cells (AT-MSC), and extra-embryonic 
stem cells [6, 7]. 
PHYSIOLOGICAL LIVER REGENERATION AND 
MECHANISMS UNDERLYING LIVER FUNCTION 
RESTORATION BY HEPATOCYTE TRANSPLANTA-
TION 
 When liver is subjected to partial hepatectomy (HP), the 
hepatocytes undergo one or two replicative cycles to restore 
loss hepatic mass. Therefore, this organ features a strong 
self-regeneration ability, when compared to other organs in 
human body. The regenerative process is tightly influenced 
by several cytokines, hormones and growth factors. In 
particular liver-resident macrophages, known as Kupffer 
cells, are involved during the initial response of the 
regenerative process, by activation of tumour necrosis factor 
α (TNF-α) pathway [8, 9]. Then, after the secretion of the 
pro-inflammatory cytokine IL-6 by Kupffer cells, hepatocyte 
proliferation begins. At this point, other factors such as 
hepatocyte growth factor (HGF), epidermal growth factor 
(EGF) and key receptors as TGF-αR are involved. Then 
hepatocyte proliferation continues until the liver mass is 
restored [8-11]. 
 When HP is higher than 70%, hepatocytes do not 
proliferate anymore, reaching a state known as “quiescent 
senescence”. To this regard it has been demonstrated that 
some liver-resident progenitor cells (oval cells in rodents or 
hepatic progenitor cells in humans), located in the proximity 
of Canals of Hering, may undergo replication and 
differentiate into both hepatocytes and cholangiocytes [12, 
13]. It was demonstrated that active Notch signalling is 
needed for cholangiocytes differentiation pathway, while 
inhibition of this signalling cascade promotes hepatocyte 
differentiation [14, 15]. 
 End-stage liver diseases all share the failure (or 
exhaustion) of liver self-repair mechanisms. Therefore, 
hepatocyte transplantation has been developed to infuse a 
cellular population which may undergo in-organ replication 
to favour hepatocyte repopulation and restoration of organ 
physiology. When liver architecture is not compromised by 
the underlying disease, the portal vein is a valid site for the 
infusion of hepatocytes, which then migrate to the liver via 
the portal system [16]. The presence of a physiologically 
intact extracellular matrix may help engrafted hepatocytes 
replication. On the contrary, when liver architecture is 
compromised, for instance in fibrotic diseases, it may be 
preferable to infuse the hepatocytes into ectopic sites such as 
the spleen, which can provide a site for hepatocyte 
proliferation [17]. To date, hepatocytes transplantation 
therapy was performed only for three categories of liver 
diseases, such as acute liver failure, inherited metabolic liver 
diseases and cirrhosis. Acute liver failure causes rapid 
deterioration of liver functions, therefore cell therapy could 
provide restoration of the main functions such as metabolism 
of toxins, secretion of proteins and stabilization of 
hemodynamic parameters. Hepatocytes transplantation in 
patients with acute liver failure were performed both via 
splenic artery or portal vein infusion [18-20]. 
 Transplantation of hepatocytes into the peritoneal cavity 
was also considered a promising approach to create a bridge 
to the spontaneous liver regeneration. Whereas infused 
hepatocytes in peritoneal space showed a limited lifespan, 
the use of alginate embedding or microcarriers for cell 
transplantation has been investigated. It was demonstrated 
that transplantation of microcarrier-attached hepatocytes into 
rats subjected to total hepatectomy improved long-term 
survival rates [21]. Cell therapy provided further 
encouraging results for the treatment of inherited metabolic 
liver diseases: in a girl with Crigler-Najjar syndrome Type I 
with hyperbilirubinaemia, infusion of hepatocytes into the 
portal vein resulted in a partial correction of plasma bilirubin 
levels for over 11 months [22]. Other positive results were 
obtained in a woman with glycogen storage disease [23] and 
in a 4-year-old girl with infantile Refsum disease [24]. 
 In end stage liver diseases such as cirrhosis, cell 
transplantation is certainly more problematic, because the 
loss of functional hepatocytes contributes to the decrease of 
liver function and disruption of organ architecture. To this 
regard, hepatocytes infusion in ectopic sites such as spleen 
may be preferable. Studies on animal models of stable liver 
cirrhosis demonstrated that rat or porcine hepatocytes [25], 
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syngeneic rat hepatocytes [17] or immortalized rat 
hepatocytes [26] infused into the spleen improved liver 
function and increased survival rate. A few clinical 
applications were performed in cases of decompensated 
chronic liver disease. As stated above, the use of 
microcarriers or other support media for hepatocytes 
transplantation in advanced cirrhosis could result in 
prolonged survival of engrafted hepatocytes [27]. 
 Recent studies showed that extra-hepatic stem cells can 
differentiate into endodermal cellular lineages such as 
hepatocytes. In particular, many groups investigated the 
therapeutic potential of hepatocyte-like cells derived from 
extra-hepatic mesenchymal stem cells [28, 29].  
Recent data from Yang and co-workers showed that co-
culture of human placenta-derived MSCs with hepatoma-
derived cells, resulted in upregulation of the metabolic 
functions in the latter, thus opening new paths for the 
therapeutic approaches based on bioartificial livers 
development [30]. To this regard, very recent data from 
Wang et al. showed that HGF exposure and direct MSCs 
contact act in a synergic fashion to inhibit liver stellate cells 
activation. This mechanism of fibrosis reduction may thus 
provide a new therapeutic option for liver diseases [31]. 
Another recent report on the use of MSCs in alleviating 
fibrosis showed that exosomes, released by human umbilical 
cord MSCs, reduced liver fibrosis, inflammation and 
collagen deposition in CCl4-induced fibrosis [32]. In 
addition, also matrix metalloproteinases, which have 
multiple roles in physiology and pathophysiology [33-35], 
have been suggested as key players in overcoming fibrosis 
effects [36]. 
PHENOTYPICAL CHARACTERIZATION AND IMM-
UNOLOGICAL FEATURES OF MESENCHYMAL 
STEM CELLS 
 The bone marrow (BM) is certainly the most common 
source of MSCs. Friedenstein and colleagues were the first 
to demonstrate that mesenchymal stem cells from bone 
marrow (BM-MSCs) are able to undergo ex vivo expansion, 
growing on plastic surface, and differentiate in various 
cellular lineages such as adipocytes [37, 38] osteocytes, 
chondrocytes, tenocytes and nervous tissue cells [39]. 
 According to the general consensus, BM-MSCs express 
typical “core” markers such as CD44, CD73, CD90, CD105, 
CD166, CD49e, CD51, CD54, CD59, CD71 [5,8-11]. 
Specific markers of the endothelial lineage, such as CD31 
and vWF [40-43] are absent in BM-MSCs, as well as 
hematopoietic markers (CD14, CD34, CD45, CD79, CD86, 
and glycophorin A-CD235a) [44, 45]. Various reports 
suggested that the use of MSCs in vivo should be safer with 
respect to formerly investigated embryonic stem cells 
(ESCs), since MSCs have higher chromosomal stability and 
do not induce neoplasm formation in the recipient host [46-
48]. However, only a minor fraction of BM cells are useful 
for regenerative medicine applications (their frequency 
ranging between 0,0001% to 0,01% of nucleated cells) [49]. 
In addition, it has been demonstrated that BM cell numbers 
significantly decrease as function of donor age [50]. 
Therefore, many researchers investigated alternative sources 
of MSCs in other easily accessible tissues, such as adipose 
and perinatal tissues: placenta, amniotic membrane, and 
umbilical cord [51-54]. 
 Moreover, in the last years the interest for MSCs in 
regenerative medicine did increase due also to their 
immunomodulatory and hypo-immunogenicity features [55]. 
The main proposed mechanisms of immunomodulation by 
MSCs involve secretion of soluble factors such as 
transforming growth factor-β (TGF- β), hepatocyte growth 
factor (HGF), prostaglandin E2 (PGE-2), indolamine 2,3 
dioxygenase (IDO). This may be due to the cross-talk 
between MSCs and T-lymphocytes [56, 57]. Moreover, cell-
cell-contacts may also have relevant roles for the 
immunomodulatory activities of MSCs [58]. As reported by 
numerous groups, main immune-related features of MSCs 
include the inhibition of T-cell proliferation and dendritic 
cell (DC) maturation and migration [59]. In addition, some 
studies suggested that MSCs may modulate T-cell 
proliferation due to their low expression of co-stimulatory 
molecules and the lack of class II HLA [58-60]. In addition, 
the immunosuppressive capacity of MSCs may also be 
mediated by the induction of T-cell anergy and regulatory T-
cells (Tregs), with significant consequences for post-infusion 
therapies [60-62]. 
 Several reports indicate that MSCs express non classical 
type I HLAs such as HLA-G (as well as its soluble form 
HLA-G5) [60,63,64], HLA-F and HLA-E [36]. To date, 
HLA-E expression has been observed in BM-MSC and WJ-
MSCs, as well as in heart-resident MSCs [36,65-68]. It has 
been also demonstrated that these class Ib MHC molecules 
are involved in the instauration of tolerance of the mother’s 
immune system toward the semi-allogeneic embryo and in 
the induction of tolerance of NK cells toward self cells [69, 
70], acting coordinately with other key molecules as Early 
Pregnancy Factor [71, 72]. Other immune-related antigens 
such as CD68 and CD14 have been also reported in WJ-
MSCs and cord lining (CL) MSCs [73,74]. In particular for 
WJ-MSCs, recent reports by us and others [75,76] 
demonstrated the expression of all three class Ib MHC 
molecules [68]. HLA-E expression has been also 
demonstrated in CL-MSCs and BM-MSC, after TNF-α 
challenge [77]. 
 Anergy is another mechanism underlying MSC-mediated 
T-cell suppression. Krampera et al. suggested that BM-
MSCs may cause T-cell arrest in G0-G1 phase through 
inhibition of cyclin D2 expression [78]. Further reports 
demonstrated that MSCs can induce immune suppression, by 
stimulation of the production of CD8+ regulatory T-cells, 
thereby inhibiting allogeneic lymphocyte proliferation [79]. 
MSCs may also affect dendritic cell (DC) differentiation, 
maturation and activation [80]. Moreover, it has been 
reported that MSCs may play an immunosuppressive role by 
influencing B-cell proliferation and activation in a dose-
dependent manner, through the modulation of their 
chemotactic abilities and antibody production [81]. Also WJ-
MSCs have been shown to possess key immunomodulatory 
activities [82], such as PGE2 and LIF (leukemia inhibiting 
factor) [83, 84]. Both molecules have been demonstrated as 
modulators of allogeneic lymphocytes proliferation in vitro 
[36]. More recently, also CD200 and its receptor have been 
demonstrated to be expressed in WJ-MSCs [85]. 
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HEPATOCYTE DIFFERENTIATION PROTOCOLS 
AND CHARACTERIZATION OF HEPATOCYTE-
LIKE CELLS 
 Mechanisms acting in early liver development have been 
widely investigated using animal models. Liver development 
requires a series of inductive signals from almost three cell 
types: mesoderm-derived cardiogenic cells, cells of the 
septum trasversum and endothelial cells. 
 In particular, in mouse embryo, at the 7-8 somites stage, 
the ventral wall of the gut is adjacent to cardiac mesoderm: 
this releases fibroblast growth factors (FGFs), which are 
needed to initiate the differentiation program towards hepatic 
fate [86]. The septum trasversum cells, by secreting bone 
morphogenetic protein-4 (BMP-4) induce the outgrowth of 
the primordial liver. Hepatocyte growth factor (HGF) 
released by endothelial cells is involved in the final 
development of the primordial liver. In addition the liver 
represents a primary hematopoietic site during development: 
it has been demonstrated that oncostatin M, secreted by 
liver-resident hematopoietic stem cells, controls late 
hepatocyte differentiation, by increasing HNF-4α expression 
[87]. 
 Based on these evidences, several in vitro hepatocyte 
differentiation protocols were developed based on the 
administration of hepatic inducers, either in a stepwise 
fashion or as a single complex mixture, to cultured cells. It 
has been reported that factors such as HGF and FGFs (such 
as FGF-2 and FGF-4), are necessary for the initial induction 
phase, while oncostatin M is involved in the final maturation 
phase of induced cells [88]. 
 Other factors which may be added to differentiation 
media include: low (1% v/v) foetal bovine serum, insulin-
transferrin-sodium selenite (ITS) supplement, dexametha-
sone at submicromolar concentrations, and epidermal growth 
factor (EGF). All of these factors may be added to 
monolayer cultures [89], to cells seeded in 3D scaffolds [90], 
or to co-culture systems in which foetal or adult hepatocytes 
are also present [91]. 
 The acquisition of a hepatocyte-like phenotype may be 
evaluated by means of several techniques. Differentiated 
cells should be able to secrete proteins such as albumin and 
alpha-fetoprotein, which can be dosed in conditioned media. 
Glycogen synthesis and accumulation may be evaluated by 
PAS (periodic acid- Schiff) staining; the inducible activity of 
cytchrome P450 isoenzymes may be assessed by specific 
assays. In addition, enzymatic activities related to the 
glucose metabolism (as that of glucose-6-phosphatase) may 
be assessed via specific assays [92]. 
 As a further datum to discriminate well differentiated 
cells, it is known that bipotential hepatoblasts can generate 
two cellular populations: hepatocytes and cholangiocytes. 
During the maturation stage of hepatocytes, there is a 
characteristic “cytokeratin switch”: bipotential precursors 
express both CK-18 and CK-19, while after proper 
differentiation the mature hepatocytes express CK-18 alone, 
while CK-19 identifies the cholangiocytes population [93-
96]. In a previous work, we demonstrated that 
undifferentiated WJ-MSCs express CK-18, CK-19, and 
HNF-4α [60]. Moreover, Zemel and collaborators [97] 
showed that naïve MSCs derived from adipose tissue 
expressed early hepatic genes such as AFP, CK-18, CK-19, 
and HNF-4α. Other authors highlighted the expression of 
AFP and transthyretin (TTR) also in the yolk sac cells [98]. 
These data collectively support the notion that expression of 
such markers may not be used as the exclusive evidence to 
demonstrate the acquisition of the desired phenotype. 
 Therefore, standard parameters which may be used in 
parallel to characterize the outcome of differentiation 
experiments may comprise: expression of key liver-specific 
transcription factors (e.g., HNF-4α, HNF-3γ, HNF-6, 
GATA-6) to evaluate the genetic reprogramming of cells 
[99-101]; evaluation of glycogen storage capacity (eg, 
visualized by PAS staining procedure) (Fig. 1) [89,102]; 
ammonia metabolism and urea production (determined by 
colorimetric or fluorometric assays) [102-104]; selective 
uptake of vital stains (eg, indocyanine green, which is 
uptaken exclusively by hepatocytes) [105]; secretion of 
plasma proteins (eg, albumin) [106,107]. Collectively, these 
assays may constitute basic reliable evidences for a 
successful hepatic differentiation. In addition, novel assays 
of prospective high specificity are being developed: recent 
data from Cui et al. further highlighted the molecular 
mechanisms leading to hepatic differentiation of human 
cord-lining mesenchymal stem cells (CL-MSCs). The 
authors characterized the micro RNA profile of both 
undifferentiated and hepatocyte-differentiated cells, 
suggesting that 25 RNAs were overexpressed and 46 were 
downregulated [108]. 
HEPATOCYTE-LIKE DIFFERENTIATIVE CAPA-
CITY BY EXTRAHEPATIC MSCS STEM CELLS: IN 
VITRO AND IN VIVO STUDIES 
 MSCs are considered useful for liver regenerative 
medicine due to their key features: self-renewal capacity, 
endodermal lineage differentiation potential and 
immunomodulatory activity [57]. Different populations of 
MSCs have been used in in vitro experiments and preclinical 
studies, to derive mature hepatocyte-like cells. 
 Bone marrow mesenchymal stem cells: In 2005, Sato et 
al. demonstrated that acute liver injury, induced by allyl 
alcohol in Sprague Dawley rats, was attenuated after 
infusion of undifferentiated BM-MSCs [109]. Later then 
other authors showed the attenuation of CCl4-induced liver 
fibrosis in rats after infusion of hepatocyte-like cells derived 
from BM-MSCs [110]. 
 Many reports demonstrated the capacity of BM-MSCs to 
differentiate towards hepatocyte-like cells (HLCs). A recent 
study, carried out by Ayatollahi et al., highlighted the 
hepatogenic differentiation potential of BM-MSCs, using 
insulin like growth factor-I (IGF-I) as a component of the 
induction medium. In liver cirrhosis, hepatocellular 
insufficiency was linked to the reduction of IGF-I levels, 
while IGF-I gene transfer may reduce the extent of fibrosis 
and improve liver function. As demonstrated by the authors, 
after 21 days of hepatic induction, BM-MSCs switched to a 
polygonal morphology, producing also higher quantities of 
albumin and AFP than undifferentiated cells. Such cells 
accumulated glycogen (assessed by PAS staining) and 
increased urea synthesis with respect to undifferentiated cells 
[111]. 
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 In a more recent report, authors differentiated BM-MSCs 
according to a previous protocol developed by Snykers 
group [112], highlighting the change of morphology by 
HLCs and expression of some hepatic markers such as CK-
18, Hep-Par antigen, alpha-1anti-trypsin (AAT) and 
albumin. In addition, differentiated cells were able to store 
glycogen and were competent for LDL uptake. However, 
results from in vivo experiments were of limited extent, since 
administration of 4x108 HLCs, to a patient with familial 
hypercholesterolemia, did not improve significantly serum 
cholesterol levels [113]. 
 One of the main liver functions is xenobiotic 
biotransformation (operated by cytochrome isoenzymes, 
CYP450). The evaluation of the activity of these enzymes is 
considered a reliable proof to confirm the acquisition of 
HLCs phenotype by MSCs. In a recent study, the authors 
investigated the upregulation of CYP450 expression in 
immortalized HLCs derived from BM-MSCs. As reported, 
both immortalized MSCs and control cells were induced to 
differentiate towards HLCs. Human hepatocellular 
carcinoma cell line (HepG2), and primary human 
hepatocytes were used as controls. The immortalized HLCs 
contained about 70% more albumin than undifferentiated 
cells and their conditioned medium featured higher urea 
levels in comparison to HepG2 cells. Moreover, the 
expression of hepatogenic-specific genes in control cells and 
HLCs was evaluated by real time PCR, and it varied on the 
basis of the hepatocyte maturation phase. However, the 
expression levels of hepatic nuclear factor4α (HNF-4α), 
glucose-6-phosphatase (G-6Pase) and tyrosine aminotrans-
ferase (TAT), were still reduced with respect to human 
primary hepatocytes. In addition, CYP450 isoenzymes were 
clearly upregulated by inducers at a level that outperformed 
the HepG2 cells used as controls [114]. 
 Other very recent reports were focused on the induction 
of hepatocyte differentiation by co-culture. Cross-talk 
between cells involves both secretion of soluble factors and 
cell-cell contact, which are important in the induction of the 
differentiation processes. 
 Deng and co-workers suggested that Kupffer cells, 
activated by liver stellate cells (LSCs), may induce BM-
MSCs differentiation towards HLCs, a mechanism mediated 
by HGF secretion [115]. More recently, Lange et al. 
demonstrated that rat BM-MSCs may be differentiated 
towards hepatocyte-like cells in presence of foetal liver cells 
(FLCs). The authors suggested that the presence of MSCs in 
the co-culture system was essential for both expansion and 
differentiation of FLCs [116]. 
As stated above, different groups demonstrated that BM-
MSC-derived hepatocyte-like cells may reduce CCl4-induced 
liver fibrosis in mice. It is still unclear which may be the 
mechanism underlying this improvement, also related to the 
best way of cellular infusion. To this regard, recent data 
provided a comparison of the therapeutic effects obtained 
using three different protocols of MSCs infusion 
(intraperitoneal, intravenous and intrahepatic 
transplantation), to treat CCl4-induced liver injury in rats. In 
particular, after differentiation towards HLCs, differentiated 
BM-MSCs labelled with DAPI were infused into different 
sites in rats. This study highlighted that intravenous injection 
resulted the best option for two reasons: first, for the higher 
number of engrafted cells and upregulation of interkeukin-10 
(IL-10); in addition, IL1β, IL-6, TNFα and TGF-β levels 
(that are associated to liver fibrosis) were lower than in the 
other groups [117]. 
 As confirmed by many studies, the use of three-
dimensional scaffolds can result in better features of 
 
Fig. (1). Representative panel of morphofunctional features of human hepatocyte-like cells (HLCs) differentiated from WJ-MSCs. HLCs 
show a polygonal morphology (B) compared to control cells which maintain their fibroblastoid aspect (A). In addition, glycogen 
accumulation may be demonstrated in HLCs by PAS staining (D), while control cells show no stain (C). Magnification 20x (A,B) and 10x 
(C,D). 
A  B 
C  D 
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transplanted cells and in an improved interaction with the 
local microenvironment. Kazemnejad and colleagues 
compared the hepatic differentiation ability of BM-MSCs in 
2D and 3D systems (biocompatible nanofibrous scaffold). 
The authors demonstrated that HLCs grown in a 3D system 
had an increased expression of hepatic markers with respect 
to cells differentiated on a 2D culture system [118]. 
 Adipose tissue-derived MSCs: According to the 
International Fat Applied Technology Society, the term 
adipose-derived stem cell (ASCs) is used to describe a 
multipotent plastic-adherent cell population derived from 
adipose tissue. 
 In a recent report Okura and colleagues differentiated 
hASCs into HLCs clusters by using a floating culture 
technique. Differentiated cells expressed hepatic markers and 
exhibited functional hepatic activities. After transplantation 
into NOD-SCID mice with chronic liver injury, both 
albumin and total bilirubin serum levels were significantly 
improved [119]. Although several studies confirmed the 
hepatic differentiation ability of hASCs, the high 
heterogeneity of primary cells still constitutes one of the 
main limits towards clinical application and may lead to a 
lack of confidence in data interpretation. The limited 
characterization of cells, or the use of a mixed population in 
in vivo assays may lead to contrasting results [54]. Russo and 
colleagues demonstrated that MSCs transplanted in liver 
spontaneously gave rise to a myofibroblast population 
therefore participating to a fibrosis process [120]. In 
addition, the possibility of cancer formation by hASCs after 
transplantation still represents an open question. 
 Umbilical cord blood-derived MSCs: Umbilical cord 
blood (UCB) has been described as a reliable source of 
hematopoietic stem cells (HSCs) compared to bone marrow 
and peripheral blood. In fact, the yield of proliferating HSCs 
derived from umbilical cord blood (UCB cells), is high and 
the isolation process is free of side effects or health risks for 
the donor, as well as ethical concerns [121, 122]. 
 Very recent data showed the hepatic differentiative 
capacity of hUCB cells. HLCs differentiation was induced 
by the administration of hepatic inducers at different steps, 
for a total of 14 days (see Table 1). Hepatocyte-like cells 
featured a polygonal shape, expressed AFP, albumin, G6P 
and CK-18. One of the novel aspects of this study was the 
shorter induction timeframe to obtain HLCs: only 14 days, as 
compared to 21 days timeframes reported in other works 
[123]. Clearly, more stringent assays will be needed in order 
to assess the adherence of these cells to the mature 
hepatocyte phenotype. 
 In another recent study, CD34+ UCB cells were 
differentiated in HLCs. After encapsulation and 
transplantation in rats with acute hepatic failure, the 
mortality rate was lower than that of non-encapsulated cells 
after 48 hours. Moreover, hematologic parameters such as 
ALT, AST and total bilirubin were significantly different 
between encapsulated and non-encapsulated cells. In 
addition, after 1-2 weeks post-transplantation, the authors 
observed the presence of fibrous tissue surrounding 
microcapsules in the greater omentum [124]. 
 Amniotic epithelial cells (AECs): Amniotic membrane 
constitutes another promising placental source for tissue 
engineering. In particular, very recent data highlighted the 
ability of cells derived from the epithelial layer of amniotic 
membrane to be differentiated towards HLCs [125, 126]. 
Seminal in vivo data came from the work of Manuelpillai 
and co-authors [127], who demonstrated that hAECs, 
transplanted into immunocompetent mice with CCl4-induced 
liver damage, successfully engrafted without evidence of 
rejection. Moreover, human proteins such as albumin and 
HLA-G were detected respectively in mouse serum and liver. 
In addition, hAECs transplantation did reduce hepatocyte 
apoptosis and serum ALT levels with respect to control 
animals. The number of activated stellate cells and the extent 
of fibrosis areas were also reduced. 
 Other recent data showed that GFP-expressing hAECs, 
when transplanted in the spleen of SCID mice, retain the 
ability to produce albumin and formed clusters of cells in 
both spleen and liver preferentially [128]. 
 Marongiu and co-workers [129] showed that hAECs 
could be differentiated towards HLCs in vitro, by using a 
combination of extracellular matrix proteins (porcine liver-
derived extracellular matrix) and growth factors (such as b-
FGF, HGF, Oncostatin M). In vitro data demonstrated that 
differentiated hAECs expressed hepatocyte markers at levels 
comparable to those of fetal hepatocytes. Also at the 
functional level, ammonia and testosterone metabolism, and 
expression of fetal inducible cytochromes suggested the 
acquisition of a HLC phenotype. The authors also performed 
transplantation of naïve hAECs into retrorsine-treated 
animals: infused cells did express liver-specific markers 
(such as HNF-4-α), enzymes (such as CYP3A4 and 
CYP2B6) and transporters (such as BSEP), at levels 
comparable to adult liver tissue [129]. More recently, the 
same research group published relevant data on the use of 
hAECs to correct in vivo a liver-related metabolic defect 
(maple syrup urine disease) [130, 131]. 
 As detailed earlier in this review, one of the most 
intriguing areas of interest for the use of perinatal stem cells 
is their role in immunomodulatory processes. Tee et al [132] 
reported new data on the immunogenicity and immunomo-
dulatory properties of HLCs derived from hAECs. The 
authors demonstrated that differentiated HLCs, while 
expressing mature liver functions, also inhibited mitogen-
induced PBMCs proliferation. The authors speculated that 
this could be due to the active secretion of immunomodu-
latory molecules by these cells, as demonstrated for IL-6, 
TGF-β1, PGE2 and HLA-G. The levels of these molecules 
were determined by ELISA in both undifferentiated hAECs 
and HLCs. The authors concluded that the retention of 
immunomodulatory properties may enable HLCs grafts to 
survive for longer periods despite their immunogenicity 
[132]. These promising data reinforce the concept that the 
maintenance of immunomodulatory properties in the 
differentiated progeny of hAECs may favor longer survival 
of grafts despite the immunogenicity of HLCs. 
 Amniotic fluid stem cells: Amniotic fluid stem cells 
(AFSCs) can be found in the human amniotic fluid 
throughout gestation and are considered promising for cell-
based therapies and tissues engineering [133]. Liver diseases 
have also been proposed as targets for AFSCs therapy. 
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Table 1. List of Studies Pertinent to the Hepatocyte-Like Differentiation of Adult and Placental Stem Cells 
Extrahepatic 
Stem Cells 
Hepatic Differentiation 
Protocol Scheme 
Analysis of Hepatic Markers Functional Assays References 
Human bone marrow-
derived mesenchymal 
stem cells 
(BM-MSC) 
Two steps-21days protocol: 
DMEM plus 10%FBS, IGF-I, 
HGF, 
dexamethasone for 7days 
14 days with addiction of OSM to 
differentiation medium 
I Albumin, AFP by ICC 
II. 
In vitro 
I.PAS staining for storage glycogen 
II. Colorimetric assay to evaluate 
urea production 
III.ELISA for albumin production 
[108] 
Human bone marrow-
derived mesenchymal 
stem cells 
(BM-MSC) 
Three step-40 days protocol: 
DMEM-LG plus FGF-4 0-3 days 
DMEM-LG plus HGF 3-6 days 
DMEM-LG with HGF, ITS and 
dexamethasone from 6 days until 
40 days 
I.Albumin,CK18, AAT, 
HepPar1 by IF 
II. Albumin, CK19, CK-19, 
AAT, TAT, HNF3β, AFP, 
LDLR, G6P, by RT-PCR 
III. Albumin by WB 
In vitro: 
I. PAS staining for storage glycogen 
II.LDL uptake 
III.Albumin and urea production by 
ELISA 
In vivo: 
Differentiated and undifferentiated 
BM-MSC together in patient with 
familial hypercholesterolemia. 
Evaluation of cholesterol levels 
[110] 
Human bone marrow-
derived mesenchymal 
stem cells 
(BM-MSC) 
Three step-23 days protocol: 
Serum free IMDM plus EGF, 
bFGF for 2 days 
IMDM plus HGF, bFGF, 
nicotinamide for 7 days 
IMDM plus OSM, dexamethasone 
and ITD for 14 days 
I.AFP,CYP3A4,HNF-4α by IF 
II. ALB AFP, CK18, G6PD, 
HNF-4a, TAT , CYP1A1, 
CYP1A2, CYP2C8, CYP2B6, 
CYP2D6, 
CYP2C9, CYP2C19, 
CYP3A4 and CYP2E1 by 
qRT-PCR 
In vitro: 
I. spectrofluorometric assay to 
evaluate urea production 
II.PAS staining for storage glycogen 
II. Cytochrome P450 assay in BM-
MSC, HepG2, and Bmi-1/hTERT 
immortalized MSC 
[111] 
Rat bone marrow-derived 
mesenchymal stem cells 
(rat BM-MSC) 
One step-21days protocol: 
α-MEM plus FBS, HGF,FGF-4, 
EGF 
I. Albumin, AFP, CK-18, by 
RT-PCR 
II.AFP, albumin by IF 
In vivo: intravenous, intraperitoneal, 
intrahepatic injection of MSC in 
CCL4-induced rat injury model. 
I. Evaluation surviving MSC, 
collagen deposition 
II. α-SMA by IHC 
III.MMP2, MMP9, TIMP1, HGF, 
PDGF, IL1β, 
IL2,IL6,IL10,IL13,INFγ, TNFα, 
TGFβ1By RT-PCR 
IV.IL-10 expression by ELISA 
V. evaluation of albumin, ALT, 
TBIL by biochemical analyzer 
[114] 
Human umbilical cord 
blood-derived 
hematopoietic stem cells 
(UCB-HSC) 
Three steps-17days protocol: 
Serum-free DMEM for 24 hours 
Serum-free DMEM plus 
EGF,bFGF for 48 hours 
H-DMEM plus 10%FBS, 
HGF,FGF-4, dexamethasone for 
14 days 
I. TO, Albumin, AFP, 
G6P,CK-18 by RT-PCR 
II. albumin, AFP by ELISA 
 [120] 
Human umbilical cord 
blood-derived 
hematopoietic stem cells 
(UCB-HSC) 
One step-16days protocol: 
Pre-conditioning: DMEM-LG with 
TPO,SCF, Flt-3 
DMEM-LG plus FBS, linoleic 
acid, ITS, L-ascorbic acid 2-P, 
FGF-4,HGF for 16 days 
I. Albumin by ICC 
II. albumin, AFP, Gata-4, by 
Rt-PCR 
In vitro: 
I albumin expression by ELISA 
In vivo: hepatic stem cells 
encapsulated and transplanted in 
abdominal cavity in rat with acute 
liver failure at 48 h after D-
Galactosamine induction. 
I. evaluation of ALT, AST, TBIL 
[121] 
Functional Hepatocytes Differentiation from MSC The Open Tissue Engineering and Regenerative Medicine Journal, 2013, Volume 6    19 
Table 1. contd… 
Extrahepatic 
Stem Cells 
Hepatic Differentiation 
Protocol Scheme 
Analysis of Hepatic 
Markers 
Functional Assays References 
Human Amniotic 
epithelial cells 
Two step, 32 days protocol. Pre-
conditioning: Serum-free DMEM 
with 100ng/mL Activin-A for 2 days, 
with 0.2% FBS for two more days 
Differentiation medium: Iscove’s 
modified Dulbecco’s medium 
(IMDM), 5% FBS, 10ng/mL EGF, 
10ng/mL FGF-2, 10ng/mL HGF, 
1µM Dex for 28 days. 
 
One step experiment with culture on 
Liver ECM substrate: 
IMDM, 10% FBS, 10 ng/mL EGF, 
10 
ng/mL FGF2 for 48 hours and then 
supplemented with 20 ng/mL HGF, 
1µM Dex, 1X ITS for 5 days. One 
additional week with 20 ng/mL OSM 
and without FGF2) 
I: Albumin, A1AT, 
CYP3A4, CYP3A7, 
CYP2A2, CYP2B6, 
ASGPR by Real-time PCR; 
In vitro: 
I. 17-hydroxyprogesterone caproate 
metabolization assay; 
II. Ammonia metabolization assay 
In vivo: 
Undifferentiated hAECs were 
transplanted in SCID/beige mice. 
Albumin, AFP, BSEP, CYPs and 
over 30 markers were analyzed by 
real time PCR 
[124] 
Human Amniotic 
epithelial cells 
One step, 21 days protocol: 
DMEM/F12 with 10% FCS, 10ng/ml 
EGF, 0,1µM, insulin, 0,1 µM DEX 
for 3 weeks. 
I. GATA-4, HNF-3β, 
Albumin, OTC, AFP, HNF-
4α by IF 
II. TDO by RT-PCR 
III. HLA class I and class II, 
CD 40, CD80, Cd86 by FC 
IV. HLA-G, PGE2, TGF-
β1, Il-6 by ELISA 
In vitro: 
I. PAS staining for glycogen 
II. CYP3A4 activity assay 
III. Urea secretion 
IV. MLR assay 
[127] 
Human Amniotic fluid 
stem cells 
ILR-1a transfected AFSCs and 
normal AFSCs cultured on collagen 
type I coated flasks. 
3 steps, 18 days protocol 
Basal medium: 60% DMEM and 
40% MCDB-201 with 2% FBS, 
PEN/STREP, 1 mg/ml linoleic-acid, 
0.1mM L-ascorbic acid, 0.03mM 
nicotinamide, 0.25mM sodium 
pyruvate, and 1.623mM glutamine. 
Hepatogenic cytokines and growth 
factors were added sequentially 
according to the following schedule. 
Days 0–2: basal medium +10ng/ml 
FGF-4; days 3–5: basal medium 
+20ng/ml HGF; days 6–18: basal 
medium +20ng/ml HGF +1× ITS and 
20 mg/l DEX +1mM trichostatin A 
I. Albumin and AFP by IF 
II. β-actin, Oct-4, AFP, and 
ALB by RT-PCR 
In vivo: 
I. AST and ALT serum levels 
II. IL-1Ra, IL-6, IL-1β and TNF-α 
plasma levels 
[129] 
Human Umbilical cord 
matrix-derived 
mesenchymal stem cells 
(UC-MSC) 
One step-until 28days in different 
support 
protocol: 
IMDM plus 15% FBS, 
dexamethasone, OSM,ITS,HGF, 
FGF-4 
I. Albumin, AFP, by ICC 
II. AFP, albumin, MTP, 
TNFα, IL-5, IL-10, TGFβ 
by RT-PCR 
III.CD68, α-SMA, albumin, 
desmin, nestin by IHC 
In vitro: 
I. Albumin by ELISA 
II. Colorimetric assay for urea 
production 
III.PAS staining for glycogen storage 
In vivo: 
undifferentiated UB-MSC 
transplanted in CCL4-induced liver 
injury mice 
I. Catalase activity by BCATm 
protein assay Kit 
[130] 
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Table 1. contd… 
Extrahepatic 
Stem Cells 
Hepatic Differentiation 
Protocol Scheme 
Analysis of Hepatic Markers Functional Assays References 
Human placental 
mesenchymal stem cells 
(hPMSC) 
Four step-35days protocol: 
Pre-conditioning: LG-DMEM plus 
FBS10% for 2 days 
IMDM plus EGF, FGF for 2 days 
IMDM with HGF, FGF, 
niacinamide, ITS, for 10 days 
IMDM plus OSM, dexamethasone, 
ITS for 10 days 
HEPATPZYME-SFM for another 
days 
I. Albumin, CK-18,CK19, 
AFP by ICC 
II. Albumin, CK-18,CK19, 
AFP, by RT-PCR 
III. albumin, CK-18 AFP by 
IHC 
In vitro: 
I.PAS staining for glycogen storage 
II.LDL-uptake 
III. spectrophotometer for urea 
production 
IV. cytochrome P450 activity assay 
In vivo: 
HPMSC transplanted in Chinese 
miniature pigs with acute liver 
failure induced by D-Galactosamine 
I. Evaluation of 
ALT,AST,ALP,TBIL,TBA 
II LIF and INF-γ by ELISA 
[135] 
Abbreviations: FBS, fetal bovine serum; IGF-I,insulin growth factor-I; OSM, oncostatin M; AFP, α-fetoprotein; FGF, fibroblast growth factor; ITS, insulin–transferrin–sodium 
selenite; CK-18, cytokeratin-18; HepPar-1, hepatocyte-paraffin-1; CK-19, cytokeratin-19; AAT, α-1-antitrypsin; TAT, tyrosine aminotransferase; HNF-3β, hepatic nuclear factor-3 β; 
LDLR, receptor low density lipoprotein; G6P, glucose-6 phosphatase, EGF, endothelial growth factor, bFGF, basic fibroblast growth factor; CYP3A4, cytochrome P450 3A4 subunit; 
HNF-4α, hepatic nuclear factor-4α; 
G6PD, glucose-6-phosphate dehydrogenase; ; CYP1A1, cytochrome P450 1A1 subunit; CYP2B6, cytochrome P450 2B6, CYP1A2, cytochrome P450 1A2 subunit; CYP2C8, 
cytochrome P450 2C8; subunit; CYP2D6, cytochrome P450 2D6 subunit; CYP2C9, cytochrome P450 2C9; subunit CYP2C19, cytochrome P450 2C19 subunit; CYP2E1 cytochrome 
P450 2E1 subunit; AHR, Aromatic hydrocarbon receptor, PXR, pregnane × receptor; CAR, constitutive aldosterone receptor; MMP2, metalloproteineasi-2; MMP9, 
metalloproteineasi-9;TIMP-1,tissue inhibitor metalloproteinases-1; 
PDGF, platelet-derived growth factor; Il1 β, interleukin-1; Il-2, interleukine-2; IL-6, interleukin-6; Il-10,interleukine-10;Il-13, interleukine-13; INFγ ,interferone- γ ; TNFα, tumor 
necrosis factor-α; TGFβ1, transforming growth factor β1;ALT, alanine aminotransferase; TBIl, total bilirubin levels in serum; TO, tryptophan 2,3 dioxygenase; TPO, thrombopoietin; 
SCF, stem cell factor; Flt-3, fetal liver tyrosine kinase-3;AST, aspartate aminotransferase, MTP, microsomal triacylglycerol transfer protein;ALP, alkaline phosphatase; TBA, total 
bile acids; LIF, leukemia inhibitory factor; MSC, mesenchymal stem cells; 
BM-MSC, bone marrow mesenchymal stem cells, ICC, immunocytochemical; IHC, immunohistochemical, RT-PCR, reverse-transcriptase-PCR, IF, immunofluorescence, qRT-PCR, 
quantitative Real time-PCR. 
 
 Zheng and co-workers [134] showed that AFSCs 
expressing IL-1Ra (interleukin-1 receptor antagonist) may 
improve fulminant hepatic failure (FHF) in an in vivo model. 
The authors showed that administration of cells prevented 
liver failure and increased animals survival. GFP-mediated 
tracking showed that the cells engrafted in host liver and 
produced albumin. Therefore the authors suggest that this 
approach may be promising for the therapy of FHF. 
 Wharton’s Jelly MSCs: Umbilical cord emerged in recent 
years as a promising source of multipotent stem cells, which 
may be isolated from all of the organ zones [135]. Very 
recent data confirmed that another reliable source of MSCs 
that can undergo hepatocyte differentiation is the umbilical 
cord matrix. A very recent work showed the capacity of WJ-
MSC-derived hepatocyte-like cells to accelerate the 
resolution of acute liver injury [136]. WJ-MSCs were 
induced to differentiate towards HLCs, by seeding them on 
different supports (plastic, matrigel and human acellular 
matrix). After 1 to 4 weeks of differentiation, the expression 
of several hepatic markers was assessed (Table 1). The 
authors analyzed the expression of albumin, AFP, 
microsomal trialcyglycerol transfer protein (MTP), 
tryptophan 2,3 dioxygenase (TDO). In addition, some 
functional assays were performed. The authors showed that 
UC-derived cells can differentiate into functional HLCs 
without any support. Moreover, the authors demonstrated 
that undifferentiated UC-MSCs, once transplanted in a 
murine model of acute liver injury (induced by CCl4), homed 
specifically at the injury site and attenuated the inflammatory 
process, resulting in a lower infiltrate, lower pro-
inflammatory cytokines levels (TNF-α, TGF-β) and 
increased levels of IL-10. In addition, UC-MSCs 
transplantation ameliorated hepatic damage by stimulating 
the activity of catalase, one of the main liver protection 
systems against ROS (reactive oxygen species) [136]. 
 More recently, Li and co-workers [32] pointed out the 
role of exosomes derived from human umbilical cord MSCs, 
which were demonstrated to alleviate liver fibrosis in vivo. 
In particular, transplantation of the sole exosomes in mice 
with CCl4-induced liver fibrosis resulted in reduced 
inflammation and collagen deposition. In addition, treated 
mice showed a recovery in serum AST levels. Interestingly, 
the authors showed also an inhibition of the EMT (epithelial-
to-mesenchymal transition), with a reduction of vimentin-
positive cells and increase of E-cadherin positive ones, with 
a positive effect on hepatocyte protection. 
Placenta-Derived Stem Cells 
 Placenta has been historically viewed as a source of cells 
and molecules with important anti-inflammatory and anti-
fibrotic actions. This is particularly true for the application of 
the intact placenta structures (such as intact amniotic 
membrane) as a therapeutic approach for over 100 years 
[137]. 
 Jung and co-workers [138] recently showed that placenta 
extracts may be used to promote liver regeneration in CCl4-
injured rats. The authors investigated the use of extracts both 
in vitro (on rat hepatic cells) and in vivo. Treated mice 
showed improved serum levels of AST/ALT. In addition, the 
reduced expression of collagen I and smooth muscle actin, 
and the increase in matrix metalloproteinase-9 expression 
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may justify the improvement in fibrosis score. In addition, 
placenta extract-treated mice showed an increase in anti-
inflammatory cytokines, ad a decrease in pro-inflammatory 
ones, thus evidencing the multiple effects of placenta 
extracts. 
 As an additional benefit, MSCs derived from human 
placenta are free from ethical issues [139,140]. A recent 
study showed that human placenta mesenchymal stem cells 
(hPMSCs) may be differentiated towards HLCs when grown 
in specific media. HLCs prolonged the survival time of pigs 
in an in vivo model of acute liver failure. In particular, 
regarding in vitro experiments, hepatocyte-differentiated 
hPMSCs expressed specific markers such as CK-18, CK-19, 
AFP and albumin, stored glycogen, synthesized urea, and 
featured inducible CYP450 enzymatic activity. Moreover, 
after transplantation in Chinese miniature pigs with D-
Galactosamine-induced liver failure, the hPMSCs improved 
liver functions: after infusion, the levels of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), cholin esterase (CHE), total bile 
acids (TBA) and total bilirubin (TBL) returned to normal 
values. Inflammatory processes and necrosis were also 
reduced. One of the important points highlighted by the 
authors was the comparative analysis between two different 
ways for cellular administration: jugular vein and portal 
vein. The authors clearly showed that infusion through portal 
vein resulted in better clinical parameters than jugular vein 
one [141]. 
 More recently, Lee and co-workers [142] performed a 
comparison of the in vitro hepatogenic differentiation 
potential of various placenta-derived stem cells and other 
adult stem cells. The authors comprehensively analyzed the 
acquisition of mature hepatocyte features in differentiated 
cells: placenta-derived cells showed a higher proliferation 
rate and higher expression of hepatocyte markers, as well as 
an increased production of HGF, which was not 
demonstrated for differentiated adult MSCs populations. 
 In another report, Jung and colleagues [143] 
demonstrated that chorionic plate-derived mesenchymal stem 
cells (CP-MSCs) isolated from placenta promoted liver 
regeneration via an autophagy-mediated mechanism. The 
expression levels of hypoxia inducible factor-1α (HIF-1α) 
and factors for autophagy, survival and regeneration, were 
significantly increased after CP-MSCs transplantation. A 
significant decrease of necrotic cells was observed as well as 
a significant increase of autophagic signals in CCl4-treated 
primary rat hepatocytes during in vitro co-culture with CP-
MSCs. 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 Stem cell therapy for liver diseases is viewed as a 
promising option in both acute and chronic settings, for the 
possibility to find a reliable alternative to orthotopic 
transplantation, or a bridge to transplant. Liver function may 
be functionally restored if transplanted cells may account for 
the 5% of the total organ mass. Albeit it can be viewed as a 
small figure, the cell numbers involved are higher than those 
achievable with other techniques, as the hepatocyte 
transplantation. Therefore the possibility to use cellular 
populations which may be infused in high numbers and bear 
functional hepatocyte features and/or immunomodulatory 
ones is of high interest (Fig. 2). In particular, fibrotic and 
inflammatory liver diseases treatments would benefit from 
the administration of cells which may, via their secreted 
 
Fig. (2). Schematic diagram showing the proposed scheme for the use of perinatal stem cells in liver regenerative medicine applications. In 
vivo applications may also benefit from the immunomodulatory features of perinatal stem cells, which may avoid(or significantly limit) the 
use of immune suppressive drugs. 
Human perinatal stem cells 
Pre‐differentiation 
towards HLCs 
Assessment of mature 
hepatocyte functions 
In vivo application in end‐stage liver diseases 
‐Specific markers expression 
‐Basic metabolic functions (glycogen and urea pathways) 
‐Inducible metabolic functions (CYP450s activities) 
‐Variable lenght from 6 to 28 days 
‐Use of clinical grade inducers (e.g. FGFs and HGF) 
‐Differentiation either on 2D or 3D cultures with  
organ‐derived matrixes 
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molecules, both reduce modifications to the tri-dimensional 
organ network, and dampen the phenomena at the basis of 
the disease, therefore allowing resident progenitors to 
replenish (and actually regenerate) the organ. 
 To this regard, research on placental stem cells increased 
in the last ten years allowing to determine new potential 
applications for the perinatal tissues, cells, extracts and 
soluble molecules. In the light of the ease of sourcing and 
culturing, inexhaustible availability and lack of ethical issues 
of these cells, their potential application as off the shelf 
therapy is increasingly favouringly viewed. 
Recent research directions are concentrated on the 
clarification of the finer molecular mechanisms behind the 
positive effects of these cells. Immunomodulation is 
increasingly viewed as one of the main processes featured by 
perinatal stem cells both in vitro and in vivo, and its intrinsic 
importance in allogeneic transplant should boost the use of 
these cells in regenerative medicine applications. In 
particular for the treatment of liver end stage diseases, the 
possibility to have additional sources of extrahepatic 
progenitors is clearly envisioned. Current treatments 
(including the standard orthotopic transplantation of the 
entire organ, or the infusion of primary hepatocytes) are 
limited by the occurrence of side effects and the lack of a 
sufficient number of donors. Recent literature data support, 
for pretty all the perinatal stem cells populations examined, 
the possibility to acquire a HLC phenotype after in vitro 
differentiation. In addition, seminal recent works strongly 
suggested that differentiated HLCs do maintain the 
expression of immunomodulatory molecules similarly to the 
parental undifferentiated cells, therefore suggesting the 
possibility to be infused in vivo without a concurrent 
standard immunosuppression protocol or with a reduced-
dosage one. Moreover, such cells would be able to perform a 
double action in the diseased organ, since capable to provide 
a functional replacement to resident hepatocytes, and favour 
the re-activation of liver self-reparative mechanisms and 
progenitor cells. 
 Overall these results are extremely encouraging and we 
expect a further expansion of the basic and applied research 
advancements aimed to the use of these cellular populations 
in regenerative medicine applications for liver diseases. 
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